Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Grossi, Francesco; Genova, Carlo; Rijavec, Erika; Barletta, Giulia; Biello, Federica; Bello, Maria Giovanna Dal; Meyer, Krista; Roder, Joanna; Röder, Heinrich

doi:10.1016/j.lungcan.2017.12.007

Cited by 16 publications

(15 citation statements)

References 36 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BR.21 trial enrolled placebo-treated patients in second or higher line (VS-G median OS, 6.6 mo; VS-P median OS, 3.1 mo; HR, 0.44; 95% CI, 0.31-0.63; p < .001) [4]. In retrospective analyses of multiple cohorts, Ver-iStrat is prognostic for OS and progression-free survival (PFS) in patients treated with front-line platinum-based chemotherapy [5]. The prognostic and predictive capabilities have been replicated in prospective analyses, in patients treated with front-line platinum and pemetrexed (VS-G median PFS, 6.5 mo; VS-P median PFS, 1.6 mo; HR, 0.36; p < .001) [6], and VeriStrat has been shown to be predictive of differential therapeutic benefit between second-line chemotherapy and erlotinib [7].…”

Section: Introductionmentioning

confidence: 99%

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

This study suggests that VeriStrat testing could enhance the prognostic role of performance status and smoking status and replicates findings from other trials that showed that the VeriStrat test identifies EGFR mutation-positive patients likely to have a poor response to EGFR tyrosine kinase inhibitors (TKIs). Although these findings should be confirmed in other populations, VeriStrat use could be considered in EGFR mutation-positive patients as an additional prognostic tool, and these results suggest that EGFR mutation-positive patients with VeriStrat "poor" classification could benefit from other therapeutic agents given in conjunction with TKI monotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients classi ed as VS-G had signi cantly longer PFS and OS than VS-P patients. These results demonstrated that VS is a strong predictive test in NSCLC patients treated with platinum-based regimens in the rst line [10]. However, so far there has been no study using this VS method for the prediction of rst-line pemetrexed plus platinum-based chemotherapy or combined with bevacizumab for Chinese advanced lung adenocarcinoma patients.…”

Section: Discussionmentioning

confidence: 88%

“…Previous studies have shown that VS was a valid method to predict the e cacy of chemotherapy or targeted therapy for advanced NSCLC patients [7][8][9][10][11]. However, so far there has been no study using VS method for the prediction of rst-line pemetrexed based chemotherapy plus for Chinese advanced lung adenocarcinoma patients without EGFR sensitizing mutations, ALK or ROS1 rearrangement.…”

Section: Introductionmentioning

confidence: 99%

Prediction of veristrat test in first-line therapy of pemetrexed based regimen for advanced lung adenocarcinoma patients

Jia

Dong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Although advanced non-squamous non-small cell lung cancer (NSCLC) patients have significantly better survival outcome on pemetrexed based treatment, a subset of patients still show intrinsic resistance and progress rapidly. Therefore we aim to use a blood-based protein signature (VeriStrat, VS) to analyze whether VS could identify the subset of patients who had poor efficacy on pemetrexed therapy. Methods: This study retrospectively analyzed 72 advanced lung adenocarcinoma patients who received first-line pemetrexed/platinum or combined with bevacizumab treatment. Results: Plasma samples from these patients were analyzed using VS and classified as Good (VS-G) or Poor (VS-P) group. The relationship between efficacy and VS status was further investigated. Of 72 patients included in this study, 35 (48.6%) were treated with pemetrexed plus platinum and 37 (51.4%) were treated with pemetrexed/platinum combined with bevacuzumab. Among all patients, 60 (83.3%) and 12 (16.7%) patients were classified as VS-G and VS-P, respectively. VS-G patients had significantly better median progression free survival (PFS) (Unreached vs. 4.2 months; P＜0.001) than VS-P patients. Besides, partial response (PR) rate was higher in VS-G than that in VS-P group (46.7% vs 25.0%, P=0.212). Subgroup analysis showed that PFS was also significantly longer in the VS-G than that in VS-P group no matter for patients received chemotherapy alone or chemotherapy plus bevacizumab.Conclusions: Our study indicates that VS could be considered as a novel and valid method to predicit efficacy of pemetrexed based therapy and identify a subset of advanced lung adenocarcinoma patients who have intrinsic resistance to pemetrexed based regimen.

show abstract

“…The VeriStrat test, originally developed for prediction of benefit from EGFR-TKIs in NSCLC, has been validated in numerous independent studies, demonstrating strong predictive [48,53] and prognostic [54][55][56] properties in various settings. For the purpose of this review we summarize the results of the application of the VeriStrat test to samples from advanced NSCLC patients treated with nivolumab in second and higher lines in the Lung cancer validation set [50], and with various immune checkpoint inhibitors in the scope of the INSIGHT registry study (NCT03289780) [49].…”

Section: The Veristrat Testmentioning

confidence: 99%

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach

Grigorieva

Asmellash

Net

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

The remarkable success of immune checkpoint inhibitors (ICIs) has given hope of cure for some patients with advanced cancer; however, the fraction of responding patients is 15–35%, depending on tumor type, and the proportion of durable responses is even smaller. Identification of biomarkers with strong predictive potential remains a priority. Until now most of the efforts were focused on biomarkers associated with the assumed mechanism of action of ICIs, such as levels of expression of programmed death-ligand 1 (PD-L1) and mutation load in tumor tissue, as a proxy of immunogenicity; however, their performance is unsatisfactory. Several assays designed to capture the complexity of the disease by measuring the immune response in tumor microenvironment show promise but still need validation in independent studies. The circulating proteome contains an additional layer of information characterizing tumor–host interactions that can be integrated into multivariate tests using modern machine learning techniques. Here we describe several validated serum-based proteomic tests and their utility in the context of ICIs. We discuss test performances, demonstrate their independence from currently used biomarkers, and discuss various aspects of associated biological mechanisms. We propose that serum-based multivariate proteomic tests add a missing piece to the puzzle of predicting benefit from ICIs.

show abstract

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Abstract: VeriStrat provides valuable clinical information that may be used to support patient-physician conversations regarding prognosis and treatment options, and to identify a subset of patients who might benefit from other treatment strategies, possibly in the framework of clinical trials.

Cited by 16 publications

References 36 publications

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Prediction of veristrat test in first-line therapy of pemetrexed based regimen for advanced lung adenocarcinoma patients

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach

Contact Info

Product

Resources

About